Touro Scholar
NYMC Faculty Publications

Faculty

5-1-2017

Hepatitis C Virus and Nonliver Solid Cancers: Is There an
Association Between HCV and Cancers of the Pancreas, Thyroid,
Kidney, Oral Cavity, Breast, Lung, and Gastrointestinal Tract?
S Qadwai
T Rehman
Jonathan Barsa
New York Medical College

Z Solangi
Edward Lebovics
New York Medical College

Follow this and additional works at: https://touroscholar.touro.edu/nymc_fac_pubs
Part of the Neoplasms Commons, Oncology Commons, and the Virus Diseases Commons

Recommended Citation
Qadwai, S., Rehman, T., Barsa, J., Solangi, Z., & Lebovics, E. (2017). Hepatitis C Virus and Nonliver Solid
Cancers: Is There an Association Between HCV and Cancers of the Pancreas, Thyroid, Kidney, Oral Cavity,
Breast, Lung, and Gastrointestinal Tract?. Gastroenterology Research and Practice, 2017, Art. ID 8349150.
https://doi.org/10.1155/2017/8349150

This Article is brought to you for free and open access by the Faculty at Touro Scholar. It has been accepted for
inclusion in NYMC Faculty Publications by an authorized administrator of Touro Scholar. For more information,
please contact touro.scholar@touro.edu.

Hindawi
Gastroenterology Research and Practice
Volume 2017, Article ID 8349150, 11 pages
https://doi.org/10.1155/2017/8349150

Review Article
Hepatitis C Virus and Nonliver Solid Cancers: Is There an
Association between HCV and Cancers of the Pancreas, Thyroid,
Kidney, Oral Cavity, Breast, Lung, and Gastrointestinal Tract?
Saad Qadwai,1 Tayyaba Rehman,2 Jonathan Barsa,1 Zeeshan Solangi,1 and Edward Lebovics1
1
2

New York Medical College and Westchester Medical Center, 100 Woods Road, Valhalla, NY 10595, USA
Bristol-Myers Squibb, 5 Research Pkwy, Wallingford, CT 06492, USA

Correspondence should be addressed to Saad Qadwai; s_qadwai@hotmail.com
Received 30 December 2016; Revised 28 March 2017; Accepted 3 April 2017; Published 3 May 2017
Academic Editor: Haruhiko Sugimura
Copyright © 2017 Saad Qadwai et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
Hepatitis C virus (HCV) is known for its oncogenic potential and has been found to be associated with hepatocellular carcinoma
(HCC) and non-Hodgkin lymphoma. It has also been postulated that HCV may play a role in the development of other
extrahepatic solid tumors of other organs of the body since it has been isolated from the vessel wall, kidney, and oral mucosa. In
this article, we have reviewed epidemiological studies that have been done to look into the relationship of HCV with nonliver
solid cancers of the pancreas, thyroid, renal, oral cavity, breast, and lung and nonpancreatic gastrointestinal cancers. Based on
this review, HCV might be associated with an increased risk of renal cell and lung cancers.

1. Introduction

2. Method

Approximately 180 million people worldwide are infected
by hepatitis C virus (HCV) including almost three million
people in the US [1, 2]. HCV virus is known for its oncogenic potential and has been found to be associated with
hepatocellular carcinoma (HCC) [3] and non-Hodgkin
lymphoma [4]. It has also been postulated that HCV may
play a role in the development of extrahepatic solid tumors
of other organs of the body since it has been isolated from
the blood vessel wall, kidney, and oral mucosa [5–7]. The
possible oncogenic eﬀects of HCV can be through various
molecular, genetic, and environmental mechanisms. These
mechanisms include complement-mediated tissue injury,
inhibition of lymphocyte-mediated apoptosis, and mutation
of somatic genes like proto-oncogenes or tumor suppressor
genes [5, 8–21]. In this article, we have reviewed epidemiological studies that have evaluated the relationship of HCV with
nonliver solid tumors.

We conducted a MEDLINE search of published articles to
identify epidemiologic studies on the potential association
between HCV infection and solid malignancies other than
HCC. We focused on the following malignancies: (1) pancreatic cancer (PAC), (2) thyroid cancer (TC), (3) renal cancer
(RC), (4) oral cancer (OC), (5) breast cancer (BC), (6) lung
cancer (LC), (7) esophageal cancer (EC), (8) stomach cancer
(SC), and (9) colorectal cancer (CRC).
The inclusion criteria of our analysis were as follows:
(1) Case-control and cohort study designs focusing on
adult population
(2) Full-text publications and peer-reviewed articles in
the English language
(3) Studies that described diagnostic testing for the HCV
infections in the participants, for example, enzyme-
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Table 1: Case-control studies for association of chronic HCV infection with pancreatic cancer (PC).
Country

Sample size (n)

HCV (+) cases
(n)/total cases (n)

HCV (+) controls
(n)/total controls (n)

Woo et al. [22]

Korea

3765

21/753

36/3012

Chang et al. [23]

Taiwan

2301

22/585

45/1716

Hasan et al. [24]

USA

1355

7/476

9/879

Author

Factors adjusted
Age, sex, DM,
smoke
Age, sex, DM,
smoke
DM, smoke,
alcohol, FHC

AOR
(95% CI)

P value

2.3 (1.3–4.0)

<0.01

1.3 (0.8–2.3)

NA

0.9 (0.3–2.8)

NA

AOR: adjusted odds ratio; CI: conﬁdence interval; DM: diabetes mellitus; FHC: family history of cancer.

linked immunosorbent assay (ELISA) and polymerase
chain reaction (PCR) for the presence of HCV RNA.
The exclusion criteria of our analysis were case reports
and case series.
The MEDLINE search of articles on the association of
hepatitis C and nonliver cancers produced the following citations: (1) PAC-: 144; (2) TC-: 65; (3) RC-: 239; (4) OC-: 179;
(5) BC-: 111; (6) LC-: 185; (7) EC-: 91; (8) SC-: 93; and (9)
CRC-: 118. We screened the potentially relevant studies
and, in accordance with predeﬁned criteria, we identiﬁed
and considered in our systematic review the following number of studies on the association of hepatitis C and nonliver
cancers: (1) PAC: 3 case-control studies and 7 cohort studies;
(2) TC: 5 case-control studies and 7 cohort studies; (3) RC: 3
case-control studies and 4 cohort studies; (4) OC: 2 casecontrol studies and 4 cohort studies; (5) BC: 2 case-control
studies and 5 cohort studies; (6) LC: 2 case-control studies
and 4 cohort studies; and (7) esophagus/stomach/colon/rectal: 2 case-control studies and 5 cohort studies.

3. Results
3.1. Pancreatic Cancers. In Woo et al., anti-HCV seropositivity was found to be associated with increased risk of developing PAC [22]. In contrary, Chang et al. and Hassan et al. did
not ﬁnd HCV infection to be associated with an increased
risk of PAC [23, 24] (Table 1).
In a population-based cohort study, Abe et al. did not
ﬁnd HCV to be associated with increased risk of PAC as
compared to individuals without a positive infection marker
in a 324,394 person-years follow-up [25]. Huang et al. conducted a nationwide cohort study in Sweden using a National
Surveillance Database from 1990 to 2006 and followed to the
end of 2008 [26]. The PAC risk in the study population was
compared with the general population [26]. In a total of
340,819 person-years in the HCV cohort, 34 PACs were
identiﬁed [26]. It was noted that HCV slightly increases the
risk of pancreatic cancer as compared to general population
[26]. El-Serag et al., conducted a cohort study including
146,394 HCV-infected and 572,293 HCV-uninfected
patients who received care at Veterans Aﬀairs health care
facilities between 1996 and 2004 [27]. In the 1.37 million
person-years of follow-up, HCV-associated risk of PAC was
slightly elevated, which was attenuated after adjusting for
alcohol use, pancreatitis, cholelithiasis or choledocholithiasis,

HBV, or primary sclerosing cholangitis [27]. An increased
risk of PAC was also noticed among HCV-infected patients
in Omland et al. [35]. However, Amin et al. did not
show an increased incidence of PAC in HCV-diagnosed
patients [28] (Table 2).
3.2. Thyroid Cancers. Five case-control studies completed in
Italy by Antonelli et al. and Montella et al. have shown consistently increased prevalence and risk of TC among patients
diagnosed with HCV infection (Table 3) [29–33]. Antonelli
et al. noted six cases of TC in 308 HCV (+) patients, while
no TC patient was noted in 616 healthy subjects from
iodine-deﬁcient areas (P 0.001) and only one TC was
noted in 616 healthy subjects from iodine-suﬃcient areas
(P 0.003) [29]. Montella et al. showed a statistically signiﬁcant association between HCV and papillary TC [30]. In
another case control study, Antonelli et al. compared the
prevalence of TC among HCV-related mixed cryoglobulinemic patients to a ﬁve sex-matched control group of subjects
aged > 50 years and who had undergone thyroid ultrasound.
They noticed two cases of papillary TC in patients with
HCV-related mixed cryglobinemia (2/94), while no case
was observed among controls (0/582) (P 0.001) [31]. In
another case-control study, Montella et al. found an association between HCV and TC in overall population and
subjects ≥ 50 years [32]. In another study, Antonelli et al.
found 3 incidences of TC on ﬁne-needle aspiration (FNA)
biopsy of HCV (+) cases while no TC was noted in HCV (−)
control group (P 0.004) [33] (Table 3). In contrary to the case
control studies, none of the cohort studies done in the United
States, Australia, Denmark, Sweden, and Taiwan showed an
association between HCV and TC [4, 28, 34–37] (Table 4).
3.3. Renal Cancers. Gonzalez et al. screened for anti-HCV
antibodies and HCV RNA in patients with suspected RC
and colon cancer (controls) [38]. They found increased
detection of anti-HCV and HCV RNA in RC cases as compared to colon cancer controls (Table 5) [38]. Malaguarnera
et al. compared the prevalence of HCV infection in cancer
patients to volunteers (controls) [39]. Increased prevalence
of anti-HCV was found in patients with RC cases as compared to control group [41]. However, Budakoğlu et al. found
no signiﬁcant increase in HCV positivity in RC patients compared to healthy control group [40] (Table 5).
In a cohort study, Gordon et al. HCV tested cases
between 1997 and 2006 were followed for the development

Denmark

USA

Omland et al. [35]

El-Serag et al. [27]

1990–2002

1996–2004

1994–2003

1990–2006

Study period
16 years
2006–2010

117,547

718,687

4204

50,953

Total number of subjects
20,360
2,143,369

17/75,834

NA/146,394

4/4204

34/39,442

PC (n)/HCV (+) cases (n)
NA/1129
19/12,126

NA

NA/572,293

NA

120/197,208

PC (n)/HCV (−) cases (n)
NA/19,231
NA/2,131,243

17

NA

4

34

OC
NA
NA

NA

NA

1

16.5

EC
NA
NA

15,980
280,676∗∗∗
1,095,911∗∗∗∗
356,775

360,154

Person-years
324,394
39.984

SIR 1.4 (0.8–2.2)

HR∗∗∗∗∗ 1.2 (1.0–1.5)

Risk (95% CI)
HR∗ 0.7 (0.3–1.7)
SRR 2.5 (1.7–3.2)
SIR∗∗ 2.1 (1.4 2.9)
HR 1.6 (1.0–2.4)
SIR 3.9 (1.1–10.1)

CI: conﬁdence interval; OC: observed cases; EC: expected cases; SRR: standardized rate ratios; SIR: standardized incidence ratios; OST: opioid substitution therapy. ∗ HR adjusted for age, sex, study area, diabetes,
BMI, and smoking. ∗∗ SIR WITH lag period after 6 months of HCV notiﬁcation. ∗∗∗ Person-years in HCV infected cohort. ∗∗∗∗ Person-years in HCV-uninfected cohort. ∗∗∗∗∗ HR adjusted for age, sex, baseline visit
date, type of visit (inpatient or outpatient) for the baseline visit, and a preceding visit, previous VA use, and era of military service.

Australia

Sweden

Huang et al. [26]

Amin et al. [28]

Country
Japan
USA

Author
Abe et al. [25]
Allison et al. [34]

Table 2: Cohort studies for association of chronic HCV infection with pancreatic cancer (PC).
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Italy

Italy

Montella et al. [32]

Antonelli et al. [33]
b

Control
Controlb
HCV diagnosis—ELISA and PCR
TC in HCV related MC
HCV prevalence in diﬀerent
cancers versus controls
130 TC cases
FNA of PTN

a

Study design

974

356

34/372
564

1540

Sample size (n)

3/139

16/130
0/835

17/226

N/A

Age, sex

HCV (+) cases
HCV (+) controls
Factors adjusted
(n)/total cases (n) (n)/total controls (n)
a
0/616
6/308
N/A
1/616b
16/130
18/242
N/A
2/94
0/582
N/A

0.001a
0.003b
0.003
0.001

P value

N/A

0.004

(a) Overall population 2.8 (1.2–6.3) (a) 0.01
(b) ≥50 years 3.1 (1.2–8.0)
(b) 0.01

3.3 (1.5–7.4)
N/A

N/A

OR (95% CI)

CI: conﬁdence interval; control—iodine deﬁcient area; control—iodine suﬃcient area; ELISA: enzyme-linked immunosorbent assay; PCR: polymerase chain reaction; MC: mixed cryoglobulinemia patients; FNA:
ﬁne-needle aspiration; PTN: palpable thyroid nodules; NA: not available.

Italy
Italy

Montella et al. [30]
Antonelli et al. [31]

a

Italy

Country

Antonelli et al. [29]

Author

Table 3: Case-control studies for association of chronic HCV infection with thyroid cancer (TC).
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USA

USA
Denmark
Australia
Australia

Giordano et al. [4]

Allison et al. [34]
Omland et al. [35]
Amin et al. [28]
Swart et al. [36]

2006–2010
1994–2003
1990–2002
1993–2007

1997–2004
2,143,369
4204
117,547
29,613

718,687
6/12,126
1/4204
9/75,834
5/14,892

NA/146,394
NA/2,131,243
NA
NA
NA

NA/572,293

Study period Total number of subjects TC (n)/HCV (+) cases (n) TC (n)/HCV (−) cases (n)
1990–2000
27,150
NA/27,150
NA

EC
NA

Person-years
Risk (95% CI)
122,272
SIR 1.5 (0.5–3.6)
HCV (+) 280,676
NA NA
HR∗ 0.7 (0.5–0.9)
HCV (−) 1,095,911
NA NA
39.984
SRR 1.1 (0.6–1.6)
1
0.5
15,980
SIR 2.1 (0.1–12.0)
9 NA
356,775
SIR 0.3 (0.2–0.7)
5
6.8
213,008
SIR 0.7 (0.2–1.7)

OE
5

OC: observed cases; EC: expected cases; CI: conﬁdence interval; SIR: standardized incidence ratio; HR: hazard ratio; ∗ HR adjusted for age, sex, race, baseline visit date, type of visit (inpatient or outpatient) for the
baseline visit and a preceding visit, previous VA use, and era of military service; NA: not available.

Country
Sweden

Author
Duberg et al. [37]

Table 4: Cohort studies for association of chronic HCV infection with thyroid cancer (TC).
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Table 5: Case-control studies for association of chronic HCV infection with renal cancer (RC).

Author
Gonzalez et al.
[38]
Malaguarnera
et al. [39]
Budakoğlu
et al. [40]

Sample size HCV (+) cases/total HCV (+) controls/total
OR (95% CI) P value
(n)
cases (n)
controls (n)
11/140∗
1/100∗
24.2
240
0.043∗∗
(2.4–>999.9)∗∗
9/11∗∗
0/1∗∗

Country

Study design

USA

Hospital-based
RCC versus CC

Italy

Case-control

536

8/15 (53%)

30/300 (10%)

N/A

<0.001

Turkey

Hospital-based cases
Controls from
general population

6170

15/903 (1.7%)

81/5267 (1.5%)

N/A

0.77

CC: colon cancer (controls); ∗ cases and controls tested for anti HCV; ∗∗ anti-HCV (+) cases and controls tested for HCV RNA; OR: odds ratio; CI: conﬁdence
interval; NA: not available.

Table 6: Cohort studies for association of chronic HCV infection with renal cancer (RC).
Author

Country

Gordon et al. [41]
USA
Hofmann et al.
Sweden
[42]
Omland et al. [35] Denmark
Amin et al. [28]
Australia

1997–2006

Total number
of subjects
67,063

RC (n)/HCV
(+) cases (n)
17/3057

1990–2006

258,000

29/43,000

NA/215,000

1994–2003
1990–2002

4204
117,547

4/4204
18/75,834

NA
NA

Study period

RC (n)/HCV
OC EC Person-years
(−) cases (n)
177/64,006 NA NA
NA
NA NA

400,196

4
18

15,980
356,775

1.1
NA

Risk
(95% CI)
HR 1.7 (1.0–2.9)
SIR 1.2 (0.8–1.7)
SMR 1.2 (0.6–2.2)
SIR 3.6 (0.9–9.2)
SIR 0.5 (0.1–3.4)

OC: observed cases; EC: expected cases; CI: conﬁdence interval; SIR: standardized incidence rate; SMR: standardized mortality rate; NA: not available.

of RC until April 2008. The adjusted hazard ratio (HR) for
age, African-American race, male gender, and chronic kidney disease (CKD) was 1.77 (95% CI 1.1–2.9, P 0.03) [41].
In contrary, another nationwide registry-based cohort study
conducted in Sweden on individuals with chronic HCV
infection diagnosed between 1990 and 2006 with a mean
follow-up time of 9.3 years did not show increased standardized incidence rate (SIR) for RC in this population. Also, SIR
was not found to be signiﬁcantly increased in Omland et al.
and Amin et al. [28, 35] (Table 6).
3.4. Oral Cancers. Nagao et al. demonstrated both signiﬁcantly increased detection of anti-HCV antibodies and
HCV RNA in patients with OC as compared to control
group. Also, signiﬁcantly decreased prevalence of anti-HCV
antibodies was noticed in patients with SC as compared to
OC patients [43]. Takata et al. found increased prevalence
of HCV antibody in patients with OC as compared to
patients with impacted teeth but the association reversed
after age adjustment [44] (Table 7).
In a prospective study done by Su et al., incidence of OCs
was 2.28-fold higher (6.15 versus 2.69 per 10,000 personyears) among patients with HCV than those in the nonviral
hepatitis group (HR 1.9, 95% CI 1.2–3.0) [45]. The positive
association was highest among individuals in the 40–49 year
age group (HR 2.57, 95% CI 1.2–5.4) [45]. However, Amin
et al. did not show an increased association of HCV with cancers of the mouth, tongue, and tonsil [28]. However, Swart
et al. showed an increased incidence of cancers of the mouth
in patients found to be HCV-positive [36] (Table 8).
3.5. Breast Cancers. Su et al. conducted a nationwide
population-based case-control study in Taiwan [46] in which

1958 patients with newly diagnosed BC were identiﬁed from
the National Health Insurance Research Database (NHIRD)
between 2000 and 2008 [46]. A randomly selected sample
of age-matched cohort of 7832 subjects without cancer was
selected for comparison [46]. Three percent of BC subjects
had HCV and 2.3% non-BC subjects had HCV [46]. No signiﬁcant association between HCV infection and BC was
found (adjusted OR 1.2, 95% CI 0.9–1.7) after adjusting for
area, occupation, urbanization, and income [46]; however,
age < 50 years was found to be associated with a 2-fold
greater risk of developing BC (OR 2.0, 95% CI 1.2–3.3)
among HCV-infected persons [46]. A single-center case control study was performed in France by Larrey et al. in which
females aged ≥ 20 years with present and/or past history of
chronic HCV infection based on detection of serum antiHCV antibodies, HCV RNA by PCR, and liver biopsy
consulting in an outpatient liver unit for 1 year [47] were
included. The control group included female patients with
other chronic liver diseases: chronic hepatitis B, alcoholic
liver disease, autoimmune hepatitis, hemochromatosis, nonalcoholic liver disease, and chronic cholangitis. The results of
this study noted a higher prevalence of BC in the HCV group
(17/294, 6%, 95% CI 3.1–8.4), but there was no signiﬁcant
statistical diﬀerence with the control group (5/107, 5%,
95% CI 0.7–8.7) [47]. Furthermore, no signiﬁcant diﬀerence
in BC was found among HCV and control group for females
younger than 40 years (0/28 versus 0/12), between 41 and 60
years (5/146, 3.4%, 95% CI 0.5–6.4 versus 1/55, 2%, 95% CI
0–5.3), and older than 60 (12/120, 10%, 95 CI 4.6–15.4 versus
4/40, 10%, 95% CI 0.7–19.3) [47].
HCV was not found to be associated with an increased
incidence of BC in cohort studies conducted by Allison
et al. (SRR 0.7, 95% CI 0.6–0.8), Omland et al. (SIR 0.25,
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Table 7: Case-control studies for association of chronic HCV infection with oral cancer (OC).
Author

Country

Nagao
et al. [43]

Japan

Takata
et al. [44]

Japan

Sample HCV (+) cases/total HCV (+) controls/total
Factors adjusted OR (95% CI) P value
size (n)
cases (%)
controls (%)
(a) Anti-HCV ab
(a) 24/100 (24)
(a) 11/104 (10.6)
(a) <0.05
204
None
NA
(b) HCV RNA
(b) 17/100 (17)
(b) 4/104 (3.9)
(b) <0.05
Anti-HCV ab∗
Hospital-based
4402
13/343
25/270
Age
0.4 (0.2–0.9)
<0.05
OC
∗∗
IT
Study design

OR: odds ratio; CI: conﬁdence interval; NA: not available; ∗∗ IT—impacted teeth (controls); ∗ anti-HCV antibodies were compared among patients with OC and IT.

95% CI 0.03–0.9), Amin et al. (SIR 0.4, 95% CI 0.3–0.5), and
Swart et al. (SIR 0.4, 95% CI 0.1–0.8) [28, 34–36].
3.6. Lung Cancers. In a Turkish retrospective study conducted by Uzun et al., anti-HCV antibodies were tested in
45 patients with LC, 80 patients with benign lung disease,
and 135 healthy controls [48]. Detection of anti-HCV abs were
signiﬁcantly higher (P < 0 05) among LC patients (3/45) as
compared to patients with benign lung disease (0/80) and the
healthy controls (1/135) [48]. In another case control study
conducted by Malaguarnera et al., increased prevalence
of anti-HCV was found in patients with LC (8/22 versus
30/300) as compared to those in the control group (36%
versus 10%, P < 0 05) [39].
In Allison et al., HCV infection was found to be associated with a slightly increased incidence of LC (SRR 1.6,
95% CI 1.3–1.9) [34]. Similarly, in Swart et al., increased incidence of cancer of trachea, bronchus, and lung were noted
(SIR 4.6, 95% CI 2.8–7.1) among subjects infected with
HCV [36]. However, in Omland et al., HCV was not found
to be associated with increased incidence of lung cancer
(SIR 1.95, 95% CI 0.93–3.58) [35]. Similarly, in Amin et al.,
HCV was not found to be associated with the increased incidence of cancer of the larynx (SIR 1.0, 95% CI 0.4–2.3) and
trachea (SIR 1.2, 95% CI 0.9–1.5) [28].
3.7. Gastrointestinal (GI) Cancers. Increased risk of EC
among HCV-infected population was not observed in the
studies done by Amin et al. (SIR 0.5, 95% CI 0.2–1.4) [28],
Allison et al. (SRR 2.1, 95% CI 0.9–3.2) [34], and Omland
et al. (SIR 1.6, 95% CI 0.04–9.2) [35]. Also, no statistically signiﬁcant association was found between HCV and SC in
Amin et al. (SIR 1.4, 95% CI 0.9–2.1) [28] and Allison et al.
(SRR 1.1, 95% CI 0.5–1.6) [34]. A case-control study by
Malaguarnera et al. found an increased prevalence of antiHCV antibodies in patients with colorectal cancer as compared to controls (8/22 (36%) versus 30/300 (10%),
P < 0 05) [39].
In Allison et al., an increased incidence of rectal cancer
was also found in patients with chronic HCV infection
(SRR 2.1, 95% CI 1.3–2.8) [34], but colon cancer incidence
rate did not increase in chronic HCV-infected patients
(SRR 0.4, 95% CI 0.3–0.6) [34]. Colon cancer incidence rate
was also not increase in HCV-infected patients in studies
by Amin et al. (SIR 0.6, 95% CI 0.5–0.9) [28] and Omland
et al. (SIR 1.0, 95% CI 0.2–2.9) [35]. Similarly, no increased
incidence of rectal cancer was observed in HCV patients in

Amin et al. (SIR 0.3, 95% CI 0.2–0.6) [28] and Omland
et al. (SIR 1.8, 95% CI 0.4–5.4) [35]. Furthermore, no
increased incidence of CRC was observed in patients with
HCV notiﬁcation (SIR 0.9, 95% CI 0.4–1.8) in Swart
et al. [36].

4. Discussion
HCV has a hepatotropic potential and is well known for
causing hepatocellular carcinoma. Since both liver and pancreas share common endodermal origin, it is postulated that
HCV may replicate in pancreatic cells as well [49, 50]. Thus,
HCV may play a role in the development of PAC. However,
most of the epidemiological studies have not shown an
association between the HCV and PAC. Among these, two
case-control studies and one cohort study were conducted
in Asian population [22, 23, 25]. Only one case-control study
done in Korea showed an increased risk of PAC in HCVpositive subjects [22]. On the other hand, focused cohort
studies which have not utilized administrative data have
not shown a positive association between HCV and
PAC [25, 27]. Based on current information, increased
PAC screening among HCV-infected patients is not
clearly indicated.
Antonelli et al. and Montella et al. collaborated to conduct ﬁve case-control studies on the association of HCV
and TC in Italy. They have consistently shown an increased
association between HCV and TC [29–33]. Although they
did not adjust for some of the TC risk factors in their analyses
such as history of radiation exposure, they were still able to
show increased risk of TC among HCV (+) population as
compared to controls from iodine-deﬁcient areas [29] and
among population ≥ 50 years [32]. However, no cohort study
has been done in Italy to conﬁrm this association between
HCV and TC. None of the cohort study done in other parts
of the world has shown any signiﬁcant relationship between
HCV and TC [4, 28, 34, 35, 37]. It could be possible that a
high prevalence of HCV in certain parts of the world may
result in an increased risk of developing TC which could be
further explained by genetic and environmental factors. Until
now, the data does not clearly support an increase in TC
screening among HCV-infected patients.
According to a study utilizing bioinformatics network
analysis technique, NY-REN-54 may be the protein responsible for a cause-outcome relationship between HCV and RCC
as this protein is common to both [51]. This protein causes
disturbance of autophagic response due to ubiquitin-

Taiwan

Australia

Australia

Su et al. [45]

Amin et al. [28]

Allison et al. [34]

1993–2007

1990–2002

1996–2008

Study period

29,613

117,547

Total number
of subjects

NA

NA

Mouth 3/14,892
Lip 3/14,892

OC (n)/HCV (−)
cases (n)
147/84796

19/75,834

OC (n)/HCV (+)
cases (n)
21/5311

Mouth 3
Lip 3

NA

NA

OC

Mouth 0.58
Lip 2.19

NA

NA

EC

OC: observed cases; EC: expected cases; CI: conﬁdence interval; SIR: standardized incidence rate; SMR: standardized mortality rate; NA: not available.

Country

Author

Table 8: Cohort studies for association of chronic HCV infection with oral cancer (OC).

213,008

356,775

78,803

Person-years

HR 1.9 (1.2–3.0)
SIR
Mouth—1.5 (0.7–3.2)
Tongue—1.1 (0.5–2.4)
Tonsil—2.1 (1.0–4.8)
SIR
Mouth—5.1 (1.0–15.0)
Lip—1.3 (0.28–4.00)

Risk (95% CI)
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protein ligase-related mechanism [51]. Among three casecontrol studies, two studies, that is, Gonzalez et al. and
Malaguarnera et al., have shown an increased risk of RCC
in HCV (+) population [38, 39]. These studies conﬁrmed
the HCV status of their subjects by testing for HCV RNA
[38, 39]. Moreover, Gonzalez et al. used CRC patients as controls in their study who are expected to have a higher risk of
acquiring HCV infection due to frequent hospitalizations
and medical procedures as compared to the general population [38]. The result of the study still showed statistically
increased prevalence of anti-HCV antibodies and HCV
RNA in the RCC patients as compared to the CRC patients
[38, 39]. Gordon et al. conducted a follow-up cohort study
to the ﬁndings of Gonzalez et al. and conﬁrmed that HCV
increases the risk of RCC [38, 41]. Based on current data,
HCV could be associated with increased risk of RCC. Clinicians should consider screening newly diagnosed RC cases
for HCV virus. Also, low threshold should be maintained
for screening RC in population positive for HCV in the US.
Few epidemiological studies have been done and most
were limited to Asia, to determine an association between
HCV and OC. The two case-control studies done in Japan
have shown conﬂicting results [43, 44]. Nagao et al. showed
increased association between HCV and OC [43]. On the
other hand, Takata et al. also showed an increased risk but
it turned into a protective eﬀect after adjusting for age [44].
A large cohort study conducted by Su et al. on Chinese
population showed an increased risk of OC in HCVinfected population as compared to HCV-negative population [45]. However, cohort studies done outside of Asian
population has not shown an association. Until now, no
deﬁnitive conclusions can be obtained from the data on the
association of HCV and OC and more studies are needed utilizing information on the risk factors of OC to be adjusted in
the data analyses for making more deﬁnite conclusions.
Epidemiologic studies on the relationship of HCV and
BC have consistently failed to show an association [28, 34–
36, 46, 47]. Only Su et al. noticed an increased risk in women
aged < 50 years [46]. Thus, recent epidemiologic data on the
association of HCV and BC do not confer a causative relationship. Therefore, increased screening of BC in chronic
HCV infection is not warranted.
Two case-control studies done in Turkey and Italy, by
Malaguarnera et al. and Uzun et al., on the association of
HCV and LC have observed that HCV increases the risk of
lung cancer [39, 48]. Until now, no cohort study has speciﬁcally looked into the association of HCV and LC. Although
the four cohort studies have shown an increased risk of LC
in HCV infected population [28, 34–36], two of them did
not ﬁnd the risk statistically signiﬁcant [28, 35]. Currently,
limited epidemiological studies have suggested some association between HCV and LC. Clinicians may consider keeping
a low threshold for screening chronic HCV infection for LC
until further more focused prospective studies evaluate the
relationship between HCV and LC in more detail.
The data on the association of HCV and nonpancreatic
GI cancers is very limited and consist mainly of a case control
study done in Italy [39] and a few cohort studies based on
administrative datasets [28, 34–36]. Malaguarnera et al.
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showed increased prevalence of anti-HCV antibodies among
CRC as compared to controls [39]. Also, Allison et al. found
increased incidence of rectal cancer in HCV-infected population [34]. None of the other cohort studies were able to
conﬁrm these associations. None of the cohort studies found
an association between HCV and EC or SC [28, 34, 35]. Thus,
it can be concluded that the current data on the association of
HCV and nonpancreatic GI cancers is very limited and does
not clearly indicate if there is an association.
Most of available data on the association of HCV and
nonhepatic solid cancers have been obtained from cohort
studies. The large size and lengthy follow-up of these studies
provides the adequate statistical power to determine the cancer risk in the study population. However, lack of consistency
has been found across the epidemiological studies on the
association of HCV and nonhepatic solid cancers which
could be explained by the limitations associated with them.
These limitations include small sample size of some casecontrol studies, errors in diagnosis in administrative dataset,
representation of only a part of the general population in the
national cancer registry, and missing data. This may result in
underestimation or overestimation of the risk and makes it
diﬃcult to interpret the results of these studies. For example,
two case-control studies done in Turkey and Italy, by
Malaguarnera et al. and Uzun et al., were limited by a small
sample size [48] and not being able to adjust for risk factors
of LC like smoking, radiation exposure, occupation, and
family history of LC [39, 48]. Similarly, Su et al. lacked information on several variables associated with BC, for example,
body mass index, fertility, and use of oral contraceptive to
adjust for confounding in their analyses [46]. Woo et al. utilized paired matching to match their controls with cases for
age, sex, and date of admission or visit but did not use conditional logistic regression for analyzing the data as indicated
when controls are pair-matched to cases [22]. Also, there
were too much missing data (66%) in this study which may
have contributed to bias to their analyses [22]. Budakoğlu
et al. did not conﬁrm the anti-HCV antibody-positive status
of the subjects with HCV RNA which could have resulted in a
bias in their analysis since anti-HCV antibodies can be falsely
positive due to old infection or secondary to cross reactivation with other infections [40]. Hofmann et al. excluded
623 HCV-infected subjects from the analyses due to
incomplete information [42]. It is not known if the characteristics of the subjects excluded from the analyses were
similar to those who were included and thus may have
resulted in a bias [42]. A large cohort study conducted
by Su et al. showed an increased risk of OC in HCVinfected population as compared to HCV-negative population [45]. However, this study also lacked information on
some of the risk factors of oral cancer like smoking, alcohol consumption, and betel squid chewing to adjust them
in their analyses [45]. Although Malaguarnera et al. observed
an increased prevalence of HCV RNA in LC patients as
compared to controls (26% versus 6.6%), they did not
conﬁrm this by using statistical analyses to look for significance [39]. Moreover, no study has looked into the role of
diﬀerent HCV genotypes in causing a speciﬁc type of
nonhepatic solid cancer.
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The data on the association between HCV and many
nonhepatic solid cancers are still in the initial stages and
are not very conclusive. More epidemiological studies are
needed in diﬀerent regions of the world to conﬁrm the associations observed in this review.
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